Arcturus Therapeutics is trading 5.4% down now at $15.29, apparently reflecting profit-taking and cooling biotechnology sentiment after substantial gains over the prior week.
- The broader market is only modestly higher, while biotechnology and pharmaceutical shares have shown signs of retreat.
- Recent coverage attributed the earlier advance to enthusiasm around positive Moderna and Merck personalized mRNA vaccine data.
- No reliable August 28 company-specific catalyst explaining the decline was identified; confidence is medium.